We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-9.09%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.4B
AUM Growth
-$3.15B
Cap. Flow
+$225M
Cap. Flow %
1.29%
Top 10 Hldgs %
85.01%
Holding
121
New
2
Increased
15
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$184M
2
KOD icon
Kodiak Sciences
KOD
+$48.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.2M
4
TSVT
2seventy bio
TSVT
+$20.9M
5
REPL icon
Replimune Group
REPL
+$19.2M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$20.1M
2
LEGN icon
Legend Biotech
LEGN
+$19M
3
OPT
Opthea Limited American Depositary Shares
OPT
+$3.19M
4
ALBO
Albireo Pharma Inc
ALBO
+$2.43M
5
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$1.55M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
76
DELISTED
Cymabay Therapeutics
CBAY
$6.75M 0.04%
2,170,464
– –
ALT icon
77
Altimmune
ALT
$580M
$6.53M 0.04%
1,072,038
– –
HRMY icon
78
Harmony Biosciences
HRMY
$2.06B
$6.01M 0.03%
123,600
– –
TNGX icon
79
Tango Therapeutics
TNGX
$4.17B
$5.68M 0.03%
750,000
– –
RVMD icon
80
Revolution Medicines
RVMD
$38.2B
$5.67M 0.03%
222,222
– –
HOOK
81
DELISTED
HOOKIPA Pharma
HOOK
$5.47M 0.03%
240,048
+170,000
+243% +$3.05M
EWTX icon
82
Edgewise Therapeutics
EWTX
$4.25B
$4.85M 0.03%
500,000
– –
ITOS
83
DELISTED
iTeos Therapeutics
ITOS
$4.84M 0.03%
150,346
– –
ALGS icon
84
Aligos Therapeutics
ALGS
$25.9M
$4.46M 0.03%
83,056
– –
NGM
85
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$4.45M 0.03%
291,801
– –
KURA icon
86
Kura Oncology
KURA
$785M
$4.41M 0.03%
274,458
-29,700
-10% -$429K
BCAB icon
87
BioAtla
BCAB
$5.46M
$4.13M 0.02%
16,500
– –
ALLK
88
DELISTED
Allakos
ALLK
$4.01M 0.02%
703,050
– –
TCRX icon
89
TScan Therapeutics
TCRX
$48.6M
$3.99M 0.02%
1,425,000
– –
MGNX icon
90
MacroGenics
MGNX
$235M
$3.9M 0.02%
442,579
– –
NVAX icon
91
Novavax
NVAX
$1.21B
$3.55M 0.02%
48,168
– –
ALEC icon
92
Alector
ALEC
$170M
$3.41M 0.02%
239,228
– –
ATYR
93
aTyr Pharma
ATYR
$47.1M
$3.34M 0.02%
625,000
– –
CYT
94
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$3.06M 0.02%
812,640
– –
DNLI icon
95
Denali Therapeutics
DNLI
$3.78B
$2.85M 0.02%
88,738
– –
KZR
96
DELISTED
Kezar Life Sciences
KZR
$2.32M 0.01%
13,968
– –
TCRR
97
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.08M 0.01%
753,064
– –
BNR
98
Burning Rock Biotech
BNR
$94M
$1.94M 0.01%
20,913
– –
SNDX icon
99
Syndax Pharmaceuticals
SNDX
$1.68B
$1.92M 0.01%
110,729
– –
AKRO
100
DELISTED
Akero Therapeutics
AKRO
$1.68M 0.01%
118,378
– –
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Baker Bros. Advisors held 121 positions worth $17.4B, down 15% from $20.6B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Trading was light in Q1 2022: portfolio turnover was 4.1%. Baker Bros. Advisors opened 2 new positions and exited 3, leaving the 121-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2022 buy was Vera Therapeutics: 333,333 shares worth $7.83M.
  • Baker Bros. Advisors added most to Incyte in Q1 2022, an estimated $184M increase.
  • Baker Bros. Advisors's biggest Q1 2022 reduction was ChemoCentryx, Inc., cutting an estimated $20.1M.
  • Baker Bros. Advisors fully exited Albireo Pharma Inc in Q1 2022, selling an estimated $2.43M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $17.4B portfolio in Q1 2022.
  • Baker Bros. Advisors opened 2 new positions and closed 3 in Q1 2022.
  • Baker Bros. Advisors's portfolio value fell 15% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q1 2022, filed 16 May 2022.